Aminotadalafil Side Effects

Reported Aminotadalafil side effects

Because aminotadalafil is assumed to behave similarly to tadalafil with the added risks of poor characterization and contamination, the side-effect profile should be considered at least as bad as tadalafil's, with uncertain additional risks. PDE5-inhibitor class side effects (likely shared with tadalafil): Headache — the most common side effect of PDE5 inhibitors, affecting 10–15% of users Flushing — vasodilation of cutaneous vessels, usually face and upper torso Nasal congestion — vasodilation of nasal mucosa Dyspepsia and gastroesophageal reflux — relaxation of the lower esophageal sphincter Back pain and myalgia — class effect of tadalafil specifically, believed related to long half-life and PDE11 cross-reactivity Visual disturbances — altered color perception, blue-green tinge, light sensitivity; more common with sildenafil than tadalafil, but uncertain for aminotadalafil given unknown PDE6 selectivity Transient hearing changes — rare but reported class-wide; cases of sudden sensorineural hearing loss have been described Dizziness and orthostatic symptoms More serious adverse events: Priapism — prolonged painful erection lasting more than 4 hours; urologic emergency requiring immediate treatment to prevent permanent erectile dysfunction Non-arteritic anterior ischemic optic neuropathy (NAION) — rare but serious; can cause permanent vision loss Severe hypotension, especially in combination with nitrates, alpha-blockers, or alcohol Cardiovascular events — MI, stroke, and arrhythmia have been reported, though causality in the context of pre-existing cardiovascular disease is complex Aminotadalafil-specific concerns beyond the class: Purity and contamination. Material detected in adulterated supplements has been found to contain impurities, unknown isomers, and variable drug content within the same product batch. Forensic testing of seized supplements has documented aminotadalafil concentrations varying by an order of magnitude across capsules of the same product. Unknown PDE selectivity profile. Inferior selectivity for PDE5 over PDE6 (visual side effects) and PDE11 (back pain, muscle aches) may be worse than tadalafil. Unknown drug-interaction profile. Metabolic pathways and CYP interactions have not been characterized in humans. Combination with other adulterants. Products containing aminotadalafil frequently also contain other undeclared pharmaceuticals, creating unpredictable interaction risks. Counterfeit and mislabeled products. A "tadalafil" product from a non-legitimate channel may in fact contain aminotadalafil, sildenafil, or a mixture. Who absolutely should not use aminotadalafil (or any PDE5 inhibitor): Anyone taking nitrates for angina or heart disease Anyone taking recreational nitrates ("poppers") — the combination can cause fatal hypotension Anyone with unstable angina, recent MI, or severe heart failure Anyone with severe liver impairment Anyone with severe hypotension or uncontrolled hypertension Anyone with a history of NAION Anyone with retinitis pigmentosa Anyone taking ritonavir, ketoconazole, itraconazole, or other strong CYP3A4 inhibitors without dose adjustment Anyone who has experienced priapism from prior PDE5 inhibitor use The practical bottom line on safety: if you have a medical indication for a PDE5 inhibitor, a licensed clinician can prescribe generic tadalafil at trivial cost. Use that route. The additional risk of consuming aminotadalafil from an unregulated supplement or bulk-research-chemical source is not justified by any benefit over the licensed drug.

When to continue, reduce, or stop Aminotadalafil

Aminotadalafil contraindications

Absolute contraindications to aminotadalafil (and all PDE5 inhibitors): Concurrent nitrate therapy — nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite, or any nitrate donor. The combination can cause life-threatening hypotension. Recent myocardial infarction (within 90 days) or unstable angina Severe heart failure (NYHA class III–IV) Severe hypotension (systolic BP below 90 mmHg) or uncontrolled hypertension (systolic BP above 170 mmHg) Recent stroke (within 6 months) History of non-arteritic anterior ischemic optic neuropathy (NAION) — PDE5i use is associated with recurrence Severe hepatic impairment (Child-Pugh C) Retinitis pigmentosa Known hypersensitivity to tadalafil or related compounds Use with guanylate cyclase stimulators (riociguat) — pulmonary hypertension drug; combination causes severe hypotension Pediatric use — not appropriate Absolute contraindication specific to aminotadalafil (beyond the class): Any situation in which regulatory oversight, manufacturing quality, and dose accuracy matter. This effectively means aminotadalafil should not be used in any legitimate medical scenario. Relative contraindications requiring medical oversight: Concurrent alpha-blocker therapy for BPH or hypertension (tamsulosin, doxazosin, etc.) — dose separation required Strong CYP3A4 inhibitor use (ritonavir, ketoconazole, itraconazole, clarithromycin, certain HIV antivirals) — dose reduction required Moderate hepatic or renal impairment — dose adjustment required Anatomic deformities of the penis (Peyronie's disease, severe fibrosis) — increased priapism risk Sickle cell disease, multiple myeloma, leukemia — increased priapism risk Bleeding diatheses or active peptic ulcer — PDE5i can increase bleeding risk Concurrent alcohol use in large amounts History of NAION in one eye — at high risk of the other eye Men using concurrent SSRIs for premature ejaculation — usually manageable but monitor for cumulative sexual dysfunction Drug interactions: Nitrates — absolute contraindication Guanylate cyclase stimulators (riociguat) — absolute contraindication Alpha-blockers — dose separation and caution CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice in very large quantities) — dose reduction CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort) — reduced PDE5i efficacy Antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics) — additive hypotension, generally manageable with routine monitoring Other PDE5 inhibitors — do not combine Populations requiring specialist evaluation before any PDE5i use: Men with known cardiovascular disease, including CAD and heart failure Men with pulmonary arterial hypertension (specialist-managed) Men on complex antihypertensive regimens Men with hepatic or renal impairment Men with a history of priapism from any cause Transplant recipients on CYP3A4-affecting immunosuppressants Older men with multiple comorbidities Baseline evaluation before beginning any PDE5i therapy: Full cardiovascular history and examination Blood pressure at rest and with positional change Current medication review, especially for nitrates and alpha-blockers Review of visual and auditory history Lipid profile, fasting glucose, A1c, basic metabolic panel Testosterone (total and free) — hypogonadism frequently co-occurs with ED Review of psychological and relationship factors Monitoring during PDE5i therapy: Response — erectile function improvement, side effects Blood pressure if on antihypertensives or alpha-blockers New vision or hearing symptoms — stop immediately if they occur New chest pain or exercise intolerance — stop and evaluate Annual cardiovascular risk reassessment The bottom line on contraindications: treat aminotadalafil's contraindication list as at least as strict as tadalafil's, with an additional implicit contraindication for the compound being an unapproved, unregulated, adulterated-supplement-associated material. For any reader with a legitimate medical indication, use prescription tadalafil from a legitimate prescriber and abandon aminotadalafil entirely.

Why vendor quality drives Aminotadalafil side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Aminotadalafil side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .